Placeholder

Idoxuridine

  • # LGM Pharma is a Idoxuridine CAS# 54-42-2 API supplier distributor based in the USA. Inquire about DMF, cGMP, price, availability, samples, sourcing, purity and more.
  • # Questions? Call our customer API support number 1-(800)-881-8210.
  • # LGM Pharma offers this active ingredient but not the finished dosage forms.
  • Inquire about this product >>

Product Details:

  • Product Name: Idoxuridine
  • CAS #: 54-42-2
  • Mode of Action:

    Idoxuridine acts as an antiviral agent by inhibiting viral replication by substituting itself for thymidine in viral DNA. This in turn inhibits thymidylate phosphorylase and viral DNA polymerases from properly functioning. The effect of Idoxuridine results in the inability of the virus to reproduce or to infect/destroy tissue.

  • Pharmacodynamics:

    In chemical structure idoxuridine closely approximates the configuration of thymidine, one of the four building blocks of DNA (the genetic material of the Herpes virus). As a result, idoxuridine is able to replace thymidine in the enzymatic step of viral replication or "growth". The consequent production of faulty DNA results in a pseudostructure which cannot infect or destroy tissue. In short, by pre-empting a vital building block in the genetic material of the Herpes simplex virus, Herplex-D topical solution destroys the infective and destructive capacity of the viral material. The virus infected cell may only be attacked during the period of active synthesis of DNA. This occurs early in the development of the Herpes simplex lesion, but at different times in different cells. Therefore, ideally, the affected area should remain saturated with the antiviral agent.

  • Metabolism:

    Idoxuridine is rapidly inactivated by deaminases or nucleotidases.

  • Toxicity:

    Hypersensitivity or increased sensitivity of eyes to light. LD50=3080 mg/kg (orally in mice).

  • IUPAC: 1-[(2R, 4S, 5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodo-1, 2, 3, 4-tetrahydropyrimidine-2, 4-dione
  • ATC: D06BB01 J05AB02 S01AD01
  • PubChem: 5905
  • DrugBank: DB00249 (APRD00504, DB03778, EXPT01835)
  • Formula: C14H16N4
  • Molecular Mass: 354.0985
  • Synonyms: 5-Iododeoxyuridine 5IDU 5IUDR Allergan 201 Allergan 211 ID2 Idossuridina [DCIT] Idoxuridin IDU IDUR Iododeoxyridine Iodoxuridine IUDR
  • SMILES: OC[C@H]1O[C@H](C[C@@H]1O)N1C=C(I)C(=O)NC1=O
  • AHFS Code: 52:04.20 84:04.06
  • InChl: XQFRJNBWHJMXHO-RRKCRQDMSA-N
  • General Reference:

    1. Seth AK, Misra A, Umrigar D: Topical liposomal gel of idoxuridine for the treatment of herpes simplex: pharmaceutical and clinical implications. Pharm Dev Technol. 2004 Aug;9(3):277-89. Pubmed
    2. Otto SE: Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine). J Intraven Nurs. 1998 Nov-Dec;21(6):335-7. Pubmed
    3. Fauth E, Zankl H: Comparison of spontaneous and idoxuridine-induced micronuclei by chromosome painting. Mutat Res. 1999 Apr 6;440(2):147-56. Pubmed

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.

API’s From Quality Manufacturers:

  • Streamlined API supply towards initial research stages as well as larger quantities of cGMP material for clinical trials and product commercialization
  • Premium quality GMP certified and fully accredited API manufacturing plants

 

  • Technical packages as well as access to filed DMF,
    ASMF or CEP (subject to availability)
  • Regulatory and technical assistance towards any
    submission type based on specific customer requirements

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. We’re working to update our website to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service